Drug Profile
Research programme: anti-infectives - AbbVie/Drugs for Neglected Diseases Initiative
Alternative Names: Neglected tropical disease therapeutics - AbbVie/Drugs for Neglected Disease InitiativeLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Abbott Laboratories; Drugs for Neglected Diseases Initiative Foundation
- Developer AbbVie; Drugs for Neglected Diseases Initiative Foundation
- Class Anthelmintics; Antiprotozoals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis; Chagas disease; Helminthiasis; Leishmaniasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in African trypanosomiasis in Switzerland
- 16 Jul 2016 No recent reports of development identified for research development in African trypanosomiasis in USA
- 16 Jul 2016 No recent reports of development identified for research development in Chagas'-disease in Switzerland